Urogen Pharma Stock Probability of Future Stock Price Finishing Over 12.2
| URGN Stock | USD 12.66 0.18 1.44% |
UroGen |
UroGen Pharma Target Price Odds to finish over 12.2
The tendency of UroGen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 12.20 in 90 days |
| 12.66 | 90 days | 12.20 | about 73.12 |
Based on a normal probability distribution, the odds of UroGen Pharma to stay above $ 12.20 in 90 days from now is about 73.12 (This UroGen Pharma probability density function shows the probability of UroGen Stock to fall within a particular range of prices over 90 days) . Probability of UroGen Pharma price to stay between $ 12.20 and its current price of $12.66 at the end of the 90-day period is about 23.66 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.41 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, UroGen Pharma will likely underperform. Additionally UroGen Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. UroGen Pharma Price Density |
| Price |
Predictive Modules for UroGen Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as UroGen Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.UroGen Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. UroGen Pharma is not an exception. The market had few large corrections towards the UroGen Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold UroGen Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of UroGen Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.31 | |
β | Beta against Dow Jones | 1.41 | |
σ | Overall volatility | 0.73 | |
Ir | Information ratio | -0.09 |
UroGen Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of UroGen Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for UroGen Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| UroGen Pharma generated a negative expected return over the last 90 days | |
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 56.7 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| UroGen Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO |
UroGen Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of UroGen Stock often depends not only on the future outlook of the current and potential UroGen Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. UroGen Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 28.8 M | |
| Cash And Short Term Investments | 137 M |
UroGen Pharma Technical Analysis
UroGen Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. UroGen Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of UroGen Pharma. In general, you should focus on analyzing UroGen Stock price patterns and their correlations with different microeconomic environments and drivers.
UroGen Pharma Predictive Forecast Models
UroGen Pharma's time-series forecasting models is one of many UroGen Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary UroGen Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about UroGen Pharma
Checking the ongoing alerts about UroGen Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for UroGen Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| UroGen Pharma generated a negative expected return over the last 90 days | |
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 56.7 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| UroGen Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO |
Check out UroGen Pharma Backtesting, UroGen Pharma Valuation, UroGen Pharma Correlation, UroGen Pharma Hype Analysis, UroGen Pharma Volatility, UroGen Pharma History as well as UroGen Pharma Performance. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.